Atika Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Atika Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-720	Closed	-$5.44M	–	98
2021 Q1	$5.44M	Sell	720 -71,280	-99%	-$5.82M	0.47%	74
2020 Q4	$6.31M	Sell	72,000 -18,000	-20%	-$1.43M	0.49%	74
2020 Q3	$6.85M	Hold	90,000	–	–	0.56%	59
2020 Q2	$11.1M	Buy	+90,000	New	+$8.94M	1.43%	20
2019 Q1	–	Sell	-9,800	Closed	-$835K	–	77
2018 Q4	$835K	Sell	9,800 -42,100	-81%	-$4M	0.25%	65
2018 Q3	$5.03M	Sell	51,900 -5,000	-9%	-$499K	0.9%	40
2018 Q2	$5.36M	Buy	56,900 +40,500	+247%	+$3.55M	1.03%	38
2018 Q1	$1.33M	Buy	+16,400	New	+$1.41M	0.46%	65
2017 Q2	–	Sell	-5,100	Closed	-$447K	–	80
2017 Q1	$447K	Buy	+5,100	New	+$454K	0.22%	61

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Atika Capital Management's BMRN Position: Q1 2024 in Review

Atika Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 85,000 shares — an estimated $8.2M sold.

Atika Capital Management first reported a position in BMRN in Q4 2014 and held it in 10 quarters. The position peaked at $8.2M in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Atika Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Atika Capital Management sold 85,000 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $8.2M.
Atika Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Atika Capital Management's BioMarin Pharmaceuticals position peaked at $8.2M in Q4 2023.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Atika Capital Management's 13F filing for Q1 2024, filed 14 May 2024.